Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD EBITDA

EBITDA at other companies

HRO
HarrowHROW
-$21.63M-101%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.05M-23.8%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$92.06M-46.3%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$52.98M-147%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$124.99M-119%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

−$59.8Mebit+
$4.1MDepreciation Depletion & Amortization
=-$55.67M

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's EBITDA?
Kodiak Sciences Inc (KOD) reported EBITDA of -$55.67M in Q1 2026.
How has Kodiak Sciences Inc's EBITDA changed year-over-year?
Kodiak Sciences Inc's EBITDA decreased by 2.2% year-over-year, from -$54.47M to -$55.67M.
What is the long-term trend for Kodiak Sciences Inc's EBITDA?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's EBITDA has grown at a -5.1% compound annual growth rate (CAGR), from -$266.05M to -$216.06M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.